More on the Honeybee Vaccine From Dalan Animal Health

The video features a long-form conversation between beekeeper and educator Bob Binnie and two representatives from Dalan Animal Health, the company behind the world’s first approved honey bee vaccine. The discussion ranges from deep skepticism about the word “vaccine” to detailed explanations of how the product works, what it costs, and how it might fit into the broader crisis of honey bee losses in 2025.​

From vaccine skepticism to curiosity

Binnie opens by admitting he was initially opposed to the idea of a “bee vaccine,” associating the word with controversial human vaccine technologies and “Frankenstein chemistry.” He says he expected to politely decline any involvement, but changed his mind after learning that Dalan’s product is not mRNA‑based and does not genetically modify bees.​

• The guests explain that their work builds on 8–9 years of research into invertebrate immunity that began long before the Covid‑19 pandemic, and that the timing of their launch unfortunately overlapped with heightened suspicion around the word “vaccine.”​

• They stress that the bee vaccine is built from dead bacteria in an aqueous solution, using a natural immune pathway bees already have, rather than any gene‑editing or mRNA platform.​

Binnie emphasizes that he is “not here to sell” the product and may never use it himself; his goal is to understand it and share information with beekeepers who are trying to navigate unprecedented colony losses.​

How the honey bee vaccine actually works

The Dalan team describes the product as essentially concentrated nature: a killed bacterial preparation (for American foulbrood) mixed into queen candy and fed to the queen and her attendants.​

• One vial contains 50 doses; the contents are kneaded into about 300 grams of queen candy, then 6 grams of that candy are placed in each queen cage along with the queen and several attendants.​

• The caged queens are kept in a dark, temperature‑controlled space (around the mid‑70s Fahrenheit) with a moisture source for seven days, during which they consume the treated candy.​

The vaccine uses a pathway called “transgenerational immune priming”: workers feed the queen, the queen’s ovaries receive “information” about specific bacterial threats, and she then passes targeted immune protection to her offspring as they develop.​

• The effect lasts for one generation; it does not permanently alter genetics and does not pass into the honey, according to the company’s lab and field testing so far.​

• Vaccinated queens produce larvae that are protected during development, including drones, but those offspring do not pass the vaccine effect on to the next generation.​

Regulators have granted Dalan a conditional license, meaning the product can be sold but the company must continue monitoring for side effects in large‑scale field use. To date, the team says they have not observed differences in queen longevity, swarming, acceptance, or honey quality between vaccinated and unvaccinated stock, but multi‑year data are still being gathered.​

Costs, ROI, and who is using it

One of Binnie’s bluntest questions is about cost—both in terms of money and trade‑offs.​

• The guests say commercial queen producers typically charge an extra $12–$18 for a vaccinated queen compared with a conventional one, which Binnie immediately labels as “ouch”‑level pricing.​

• They argue that, in many operations, improved brood patterns, stronger early‑season buildup, and 12–18% higher honey yields can repay that investment, especially in marginal or poor nectar years.​

They cite examples such as a Canadian breeder who saw vaccinated colonies retain their honey during a “green dirt” year (plenty of foliage but no bloom), while unvaccinated colonies consumed their stores and were expected to die before winter.​

As of the interview, the company estimates around 30 queen producers across the US and Canada are using the vaccine, covering a wide range of stocks (Italians, Carniolans, Russians, and others). Canada initially showed strong conceptual interest, but regulatory requirements to go through veterinarians, plus tariffs and added costs, have slowed adoption there.​

Dalan also notes a discount program for beekeepers in response to the severe 2025 colony losses, reducing the effective per‑queen vaccine cost roughly by half for those willing to vaccinate queens themselves.​

Limits and questions: EFB, viruses, and evolution

The conversation is frank about uncertainties and limitations.

• While the vaccine is targeted at American foulbrood (AFB), field results on European foulbrood (EFB) have been inconsistent: some apiaries saw apparent benefits, others saw none, likely due to regional variation and multiple strains of the EFB bacterium.​

• The team is more excited about observed reductions in deformed wing virus (DWV) loads in vaccinated colonies, though they frame this as an indirect benefit of healthier, less disease‑burdened hives rather than a direct antiviral product.​

On the evolutionary question—whether vaccination might prevent bees from naturally developing resistance—the guests argue that the product simply leverages an existing pathway bees already use when exposed to contaminated food; they see it as “accelerating” a natural process rather than blocking adaptation.​

They also discuss shifting DWV dynamics: older DWV‑A strains versus increasingly troublesome DWV‑B, which appears to be more damaging at lower mite levels and may help explain why acceptable mite thresholds keep dropping.​

The broader 2025 crash: mites, viruses, and management

Beyond the vaccine, a large part of the video grapples with the massive 2025 bee die‑off, especially in California almond pollination.

• A “working theory” shared by many commercial beekeepers is that a strong, extended honey flow in 2024 delayed mite treatments; by the time beekeepers treated, mite levels were already high and had transmitted heavy viral loads.​

• Even when mite treatments later knocked infestations down to near zero, the virus burden in adult bees and brood remained, leading to delayed collapses months later, often as colonies came out of winter.​

The Dalan team notes that historical graphs show recurring deep dips in bee populations roughly every couple of decades, often without a clear identified cause, and they speculate about possible overlaps with climate cycles and modern climate disruption.​

They criticize how rarely commercial operators test for viruses or bacteria, pointing out that in other crops it is standard to constantly test leaves, fruit, and soil, whereas many beekeepers see little point in virus testing when there has been no preventive tool available. Their hope is that preventive health (including vaccination and more rigorous monitoring) will become as normal in beekeeping as in cattle, poultry, and swine.​

Adoption patterns and the future of bee health

Interestingly, the guests say some of the strongest organic interest is not from the biggest migratory pollinators but from sideliners, well‑educated hobbyists, and smaller commercial outfits who attend bee expos and are looking for every edge they can get.​

• Large pollination outfits are often running “as hard and fast as they can,” with limited bandwidth for experimenting, tracking extra metrics, or changing systems until something forces a shift.​

• Sideliners and serious hobbyists, by contrast, may have the time and mindset to try new tools, compare vaccinated and unvaccinated stock, and adopt practices like selective breeding for mite resistance alongside vaccines and other IPM approaches.​

Binnie closes by reinforcing that, while he’s impressed by the transparency and research, he still views his role as educational rather than promotional. He notes that his own operation will continue breeding for resistance and tightening mite management, and that the vaccine is one more tool beekeepers can consider in a rapidly changing, high‑pressure environment.​

Taken as a whole, the interview presents the honey bee vaccine not as a magic bullet for the 2025 crisis, but as an early preventive tool emerging at the same time the industry confronts record losses, shifting viruses, and the limits of “business as usual” beekeeping in North America.